Should The FDA Force Drug Makers To Discuss Their Clinical Trials?

By |2017-04-25T18:03:53+00:00December 1st, 2014|Pharma News|

http://www.forbes.com/sites/johnlamattina/2014/12/01/should-the-fda-force-drug-makers-to-discuss-their-clinical-trials/ Companies are not required to meet with the FDA to discuss their trial design. Nor are they required to follow their recommendations. As revealed in a recent research letter to the Journal of the American Medical Association (JAMA) ), of the 35 drugs approved from February 1, 2011 to February 29, 2012, companies met [...]

Read More
Comments Off on Should The FDA Force Drug Makers To Discuss Their Clinical Trials?

Studyops Awarded Fibromyalgia Clinical Trial , Screening will begin in December

By |2014-11-26T16:21:09+00:00November 26th, 2014|Pharma News|

Studyops, San Francisco, CA. 11/26/2014, and the Center for Occupational Health received an award for a new RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED Clinical Trial for patients with Fibromyalgia. Dr Viladimir Bokarius will be the lead principal investigator for the project, which will take place in our Richmond California location. Studyops continues to be the Sponsor's choice [...]

Read More
Comments Off on Studyops Awarded Fibromyalgia Clinical Trial , Screening will begin in December

STUDYOPS and OPTIMUS MEDICAL AWARDED 2 HIV TRIALS

By |2014-11-25T18:54:18+00:00November 25th, 2014|Pharma News|

Studyops and Optimus, San Francisco, CA. were awarded 2  Studies for patients with HIV. Screening will begin in January. Check out www.studyops.com for our contact information to answer any questions. Please welcome Optimus, Dr. Shawn Hassler and his team to the Studyops family.

Read More
Comments Off on STUDYOPS and OPTIMUS MEDICAL AWARDED 2 HIV TRIALS

C-Suite unrest in Big Pharma

By |2014-11-25T18:22:48+00:00November 25th, 2014|Pharma News|

http://www.fiercepharma.com/story/takedas-us-chief-bows-out-amid-management-shake/2014-11-25?utm_medium=nl&utm_source=internal Takeda Chief is out, EVP Lise Kingo at Novo is out, Allergan pruning the Executive offices, plenty of others. All the M&A buys pipelines, but surely does not guarantee FDA follow through. www.studyops.com

Read More
Comments Off on C-Suite unrest in Big Pharma

Health Experts: Say No to Randomized Trials Testing Ebola Drugs

By |2017-04-25T18:03:53+00:00November 24th, 2014|Pharma News|

Karla Burke Life Sciences Senior Marketing Specialist at Thomson ReutersTop Contributor Leading health experts said that having decided it is ethical to use non-approved products to help deal with the Ebola virus epidemic, it would be unethical if those drugs were administered in the context of randomized clinical trials. “No one insisted Western medical workers [...]

Read More
Comments Off on Health Experts: Say No to Randomized Trials Testing Ebola Drugs

Quorum Review’s New Offering for Phase I Ebola Studies

By |2014-11-21T15:17:38+00:00November 21st, 2014|Pharma News|

With the Ebola virus becoming a major global healthcare crisis, Quorum Review IRB recognizes the imperative nature for developing new vaccines and treatments quickly. To assist investigators, medical institutions, as well as pharmaceutical sponsors and CROs, we are offering initial board review for Phase I Ebola studies at NO CHARGE. http://us1.campaign-archive1.com/?u=75cdd3197c4f2f278789c2b54&id=fe3bcb24d8&e=728640ad3b

Read More
Comments Off on Quorum Review’s New Offering for Phase I Ebola Studies

World Drug Bill Will Reach $1.3 Trillion By 2018

By |2017-04-25T18:03:54+00:00November 20th, 2014|Pharma News|

The world spends most of its money on medicine. New study reveals that by the year 2018 the world drug bill will reach approximately $1.3 trillion. The new treatments for cancer and hepatitis C contribute to the rise. Another factor for this increase are the people that buy pharmaceuticals using their rising incomes. The new [...]

Read More
Comments Off on World Drug Bill Will Reach $1.3 Trillion By 2018

Payers’ hep C delay tactics work: Coverage hurdles may be dampening Harvoni script growth

By |2017-04-25T18:03:54+00:00November 19th, 2014|Pharma News|

Gilead's ($GILD) hep C wonder combo, Harvoni, boasts cure rates as high as 99.1%, and analysts have said they expect it to rack up $10 billion a year in sales, becoming the fastest-growing drug of all time on the way there. But if all of that's the case, then why are U.S. scripts lagging [...]

Read More
Comments Off on Payers’ hep C delay tactics work: Coverage hurdles may be dampening Harvoni script growth
Go to Top